Shots:
- TrueLab has granted Bionyra exclusive worldwide rights, excl. Greater China, to research, develop, manufacture, & commercialize TL-001, an anti-TL1A monoclonal antibody, & TL-003, a TL1A × IL-23p19 bispecific antibody
- As per the deal, TrueLab will receive ~$985M in total consideration, incl. an upfront payment as well as development, regulatory, & commercial milestone payments, with tiered royalties on future net sales
- TrueLab will receive a single-digit equity stake in Bionyra, following its $165M Series A financing, co-led by Jeito Capital & Sofinnova Partners. The deal also gives Bionyra the option to advance additional preclinical programs from TrueLab under a similar framework
Ref: PRnewswire | Image: TrueLab & Bionyra | Press Release
Related News: Insilico Medicine and SK Biopharmaceuticals Sign AI-Driven Drug Discovery Deal Worth Up to $2.5B for Neuroimmune Disorders
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
